Home > Insider Trading > Filing (0001181431-10-058220)

Filing Details

Accession Number:: 0001181431-10-058220
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-11-30 19:03:43
Reporting Period:: 2010-11-29

Filing Date:: 2010-11-30
Accepted Time:: 2010-11-30 19:03:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1375151	Zogenix Inc.	ZGNX	Pharmaceutical Preparations (2834)	205300780

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1166285	Michael Steinmetz	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1249153	Dennis Henner	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1252522	Nicholas Galakatos	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1252523	Robert Liptak	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431403	Nicholas Simon	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431441	Clarus Ventures I, Llc	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431445	Clarus Lifesciences I, L.p.	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 92130	No	No	Yes	No
1505590	Clarus Ventures I Management, L.p.	C/O Clarus Ventures , Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-11-29	2,100,000	$0.00	2,100,000	No	4	C	Direct
Common Stock	Acquisiton	2010-11-29	1,247,947	$0.00	3,347,947	No	4	C	Direct
Common Stock	Acquisiton	2010-11-29	884,492	$0.00	4,232,439	No	4	C	Direct
Common Stock	Acquisiton	2010-11-29	1,750,000	$4.00	5,982,439	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2010-11-29	21,000,000	$0.00	2,100,000	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-11-29	12,479,474	$0.00	1,247,947	$0.00
Common Stock	8% Convertible Promissory Note	Disposition	2010-11-29	884,492	$0.00	884,492	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each of the Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock automatically converted to Common Stock upon the closing of the Issuer's initial public offering on November 29, 2010 at a conversion ratio of one share of Common Stock for every ten shares of Series A-1 Convertible Preferred Stock and one share of Common Stock for every ten shares of Series B Convertible Preferred Stock, as applicable, rounded down to the next whole number, for no additional consideration.
These securities are held of record by Clarus Lifesciences I, L.P. ("CLI"). Clarus Ventures I Management, L.P. ("CVIM LP") is the general partner of CLI, and Clarus Ventures I, LLC ("CVI LLC") is the general partner of CVIM LP. As such, CVI LLC and CVIM LP may each be deemed to share voting and dispositive power with respect to the securities owned by CLI, but each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Each of Messrs. Galakatos, Henner, Liptak, Simon and Steinmetz is a manager of CVI LLC and a general partner of CVIM LP and in such capacities may be deemed to beneficially own the securities held of record by CVI, but each disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The principle of the Note and accrued interest thereon was automatically converted upon the closing of the Issuer's initial public offering on November 29, 2010 into shares of Common Stock at a conversion price equal to $4.00 per share, the per share price of the Common Stock sold in the Issuer's initial public offering.
The filing of this statement shall not be deemed an admission that, for the purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of equity securities covered by this statement.